

Importance of discovery and clinical testing in orphan drug development

FIGON Geneesmiddelen dagen

October 7, 2008

Congrescentrum de Werelt, Lunteren - Videzalen

Speaker	Time	Affiliation	Subject
Prof. Dr. Herjan Coelingh Bennink (chair)	11:00-11:05	Pantarhei	Introduction part 1 (discovery)
Dr. Remco de Vruhe	11:05-11:30	WGM	Ultra rare disorders: Personalized but no medicines
Dr. Johan Tjhuis	11:30-12:00	Specs	Drug discovery & finding leads in practice: background, practical examples & results, possibilities to booster drug development for rare diseases
Dr. Cees van Veldhuizen	12:00-12:30	Orphan Drugs NL	Serendipity and inventiveness were the keys for repositioning Levamisole as an orphan drug
Prof. Dr. Herjan Coelingh Bennink (chair)	12:30-12:35	Pantarhei	Concluding remarks
Lunch & poster session	12:35-14:30	NA	NA
Prof. Dr. Herjan Coelingh Bennink (chair)	14:30-14:35	Pantarhei	Introduction part 2 (clinical testing)
Drs. Harald Heemstra	14:35-15:00	UU	Predictors of orphan drug failure in the European Union
Dr. Kim Wever	15:00-15:30	VSOP	PatientPartner: Identifying the needs for patients partnering in clinical research
Dr. Rolf Boot	15:30-16:00	AMC	Importance of knowledge on biomarkers of disease on success of clinical development
Tea break	16:00-16:30	NA	NA
Dr. Eva Morava	16:30-17:00	UMCN	Natural course of disease in inborn errors: how to evaluate the success of treatment in orphan diseases
Dr. Jaap de Boer	17:00-17:30	Genzyme	Industry perspective on clinical development of orphan drugs: practical aspects, critical factors, results
Prof. Dr. Herjan Coelingh Bennink (chair)	17:30-17:35	Pantarhei	Concluding remarks